Form 4: Guardant Health Director Steve Krognes Reports RSU Vesting and Stock Acquisition

Guardant Health, Inc. Director Steve E. Krognes reported the acquisition of 154 shares of common stock through the vesting of restricted stock units, increasing his direct beneficial ownership to 10,991 shares.

Summary

• Steve E. Krognes, a Director at Guardant Health, Inc. (GH), reported a change in his beneficial ownership.
• On May 31, 2025, Krognes acquired 154 shares of Guardant Health Common Stock.
• This acquisition resulted from the exercise or conversion of derivative securities, specifically Restricted Stock Units (RSUs), at a price of $0 per share.
• Following this transaction, Krognes directly beneficially owns 10,991 shares of Common Stock.
• He also directly beneficially owns 2,006 Restricted Stock Units.
• The RSUs involved were granted on August 9, 2022, with 25% vesting on June 30, 2023, and the remaining 75% vesting in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter.

Sentiment

Score: 7

Explanation: The filing reports a routine insider transaction (RSU vesting) which increases the director's direct ownership, generally viewed as a neutral to slightly positive signal of alignment, but provides no new operational or financial information.

Positives

• Director Steve Krognes increased his direct beneficial ownership of Guardant Health common stock, which can be seen as a positive sign of confidence in the company.
• The acquisition was due to the vesting of Restricted Stock Units, a common form of equity compensation, aligning management's interests with shareholders.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook, as its purpose is solely to report an insider transaction.

Management Comments

• "This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter."

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects standard equity compensation practices within the biotechnology or healthcare diagnostics sector.

Comparison to Industry Standards

• As a standard insider transaction report (Form 4), this document does not provide financial or operational results that can be directly compared to industry benchmarks or specific comparable companies/projects. It merely reports a change in an insider's stock ownership due to RSU vesting, which is a common compensation mechanism across industries.

Stakeholder Impact

• Shareholders: The increase in a director's direct ownership through RSU vesting aligns the director's interests more closely with shareholders.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Ownership, Equity Compensation, Beneficial Ownership